EU firms targeted in calls for new biomarkers and drug development tools
This article was originally published in SRA
Personalised medicine, biomarkers and systems biology are among the collaborative projects aimed specifically at small and medium-sized companies in the latest call for proposals under the EU's funding programme, FP71-3.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?